AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9796881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 25 mg (once daily for 10 days)
Number of subjects: 21
Study 9796881 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (once daily for 10 days)
Number of subjects: 21
Study 9796881 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 10 days)
Number of subjects: 21
Study 7549418 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of Vasoactive Intestinal Polypeptide (VIP)
Number of subjects: 20
Study 7549418 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection of Substance P (SP)
Number of subjects: 20
Study 7549418 — intervention group
Group type: COMPARATOR
Intervention: Methacholine-induced sweating
Number of subjects: 20
Study 7549418 — intervention group
Group type: EXPERIMENTAL
Intervention: Flare responses to VIP and SP
Number of subjects: 20
Study 2229528 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (125 mg taken twice daily)
Number of subjects: 41
Study 2229528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 628824 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy with pyloroplasty
Number of subjects: 64
Study 628824 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy without pyloroplasty
Number of subjects: 64
Study 31344386 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical coal tar treatment
Number of subjects: 17
Study 31344386 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment (control)
Number of subjects: 17
Study 30251749 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interfascial injection (US-IFI)
Number of subjects: 62
Study 30251749 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided nerve stimulating technique (US-NS)
Number of subjects: 62
Study 30251749 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 62
Study 27150460 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin and lactoperoxidase-containing tablets
Number of subjects: 46
Study 27150460 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 46
Study 26187496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine (up to 200mg per day, up to 400mg if taking combined oral contraceptives)
Number of subjects: 0
Study 26187496 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 0
Study 23528074 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% PVP-I
Number of subjects: 241
Study 23528074 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% PVP-I
Number of subjects: 241
Study 23528074 — intervention group
Group type: COMPARATOR
Intervention: Iodine-free antiseptic
Number of subjects: 241
Study 21511526 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive distraction (ignoring tones)
Number of subjects: 12
Study 21511526 — intervention group
Group type: COMPARATOR
Intervention: Active distraction (reacting to target tone)
Number of subjects: 12
Study 21511526 — intervention group
Group type: COMPARATOR
Intervention: No distraction condition
Number of subjects: 12
Study 21511526 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor imagery
Number of subjects: 12
Study 21511526 — intervention group
Group type: EXPERIMENTAL
Intervention: Other mental tasks (word association, mental subtraction, spatial navigation)
Number of subjects: 12
Study 19702677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 12921
Study 19702677 — intervention group
Group type: COMPARATOR
Intervention: UFH plus GP IIb/IIIa inhibitor
Number of subjects: 12921
Study 17365760 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1,800 mg/day for 8 weeks
Number of subjects: 50
Study 15231010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral daily ibandronate (2.5 mg)
Number of subjects: 2946
Study 15231010 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral intermittent ibandronate (20 mg every other day for 12 doses every 3 months)
Number of subjects: 2946
Study 15231010 — intervention group
Group type: COMPARATOR
Intervention: Oral ibandronate (daily and intermittent)
Number of subjects: 2946
Study 11234783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM)
Number of subjects: 383
Study 11234783 — intervention group
Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR)
Number of subjects: 383
Study 11234783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM) for women
Number of subjects: 383
Study 11234783 — intervention group
Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR) for women
Number of subjects: 383
Study 11234783 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-delivered partner medication (PDPM) for casual partners
Number of subjects: 383
Study 11234783 — intervention group
Group type: COMPARATOR
Intervention: Patient-based partner referral (PBPR) for casual partners
Number of subjects: 383
Study 9678620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for 5 years) in adjuvant studies
Number of subjects: 321
Study 9678620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg/day for 5 years) in chemoprevention study
Number of subjects: 321
Study 9678620 — intervention group
Group type: COMPARATOR
Intervention: Placebo in chemoprevention study
Number of subjects: 321
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 30, 50, or 70 micrograms.kg-1
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 100, 200, 250, or 300 micrograms.kg-1
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rocuronium and mivacurium (1 ED50 rocuronium + 1 ED50 mivacurium, etc.)
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms.kg-1
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 150 micrograms.kg-1
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 150 micrograms.kg-1 + Mivacurium 37.5 micrograms.kg-1 (Group 3)
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 300 micrograms.kg-1 + Mivacurium 75 micrograms.kg-1 (Group 4)
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms.kg-1 + Mivacurium 150 micrograms.kg-1 (Group 5)
Number of subjects: 160
Study 8053589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of rocuronium 150 micrograms.kg-1 + Mivacurium 37.5 micrograms.kg-1 (Group 3)
Number of subjects: 160
Study 2903169 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (40 mg, orally)
Number of subjects: 21
Study 2903169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 2903169 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (iv administration 20 min before GIT)
Number of subjects: 21
Study 31578273 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors (ICPIs)
Number of subjects: 0
Study 29440887 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol 15 µg, twice daily
Number of subjects: 841
Study 29440887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 841
Study 29440887 — intervention group
Group type: EXPERIMENTAL
Intervention: Arformoterol responders
Number of subjects: 841
Study 29440887 — intervention group
Group type: COMPARATOR
Intervention: Placebo responders
Number of subjects: 841
Study 27027204 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine (NAC)
Number of subjects: 31
Study 27027204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 25267385 — intervention group
Group type: EXPERIMENTAL
Intervention: External Facilitator (EF)
Number of subjects: 1600
Study 25267385 — intervention group
Group type: EXPERIMENTAL
Intervention: External Facilitator plus Internal Facilitator (EF/IF)
Number of subjects: 1600
Study 23502689 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help cognitive behavioral therapy (CBT) package (Overcoming Bulimia Online)
Number of subjects: 8
Study 19952780 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-pressure group (n = 114)
Number of subjects: 228
Study 19952780 — intervention group
Group type: COMPARATOR
Intervention: Office pressure group (n = 114)
Number of subjects: 228
Study 19069453 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional therapy (CT) with aspirin (125 mg thrice daily)
Number of subjects: 30
Study 19069453 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronotherapy (ChN) with aspirin taken once daily at 22.00
Number of subjects: 30
Study 19069453 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 16809906 — intervention group
Group type: EXPERIMENTAL
Intervention: PSE/DAG (1.2 g PSE/30 g DAG for 2 weeks)
Number of subjects: 0
Study 16809906 — intervention group
Group type: COMPARATOR
Intervention: TAG mayonnaise (control)
Number of subjects: 0
Study 14719295 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment in the treatment group
Number of subjects: 46
Study 14719295 — intervention group
Group type: COMPARATOR
Intervention: Drugs in the control group
Number of subjects: 46
Study 11703280 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐s sustained freeze with liquid nitrogen
Number of subjects: 200
Study 11703280 — intervention group
Group type: COMPARATOR
Intervention: Traditional freeze with liquid nitrogen
Number of subjects: 200
Study 9208339 — intervention group
Group type: EXPERIMENTAL
Intervention: Incadronate (0.025-1.6 mg) in healthy volunteers
Number of subjects: 0
Study 9208339 — intervention group
Group type: EXPERIMENTAL
Intervention: Incadronate (2.5-10.0 mg) in patients with malignancy-associated hypercalcemia
Number of subjects: 0
Study 7956408 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple saline solution nasal irrigation
Number of subjects: 30
Study 7956408 — intervention group
Group type: EXPERIMENTAL
Intervention: Large particle water vapor at 43 degrees C
Number of subjects: 30
Study 7956408 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular water vapor at 41 degrees C
Number of subjects: 30
Study 2443363 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy
Number of subjects: 306
Study 2443363 — intervention group
Group type: COMPARATOR
Intervention: Sequential chemotherapy
Number of subjects: 306
Study 29369166 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/day)
Number of subjects: 40
Study 29369166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28698390 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Intervention
Number of subjects: 62
Study 28698390 — intervention group
Group type: COMPARATOR
Intervention: Wait List Control
Number of subjects: 62
Study 25381344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 24
Study 25381344 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Number of subjects: 24
Study 25381344 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration
Number of subjects: 24
Study 22928476 — intervention group
Group type: EXPERIMENTAL
Intervention: AS(100)
Number of subjects: 0
Study 21535040 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training using a 30-minute audio CD prior to the procedure
Number of subjects: 61
Study 21535040 — intervention group
Group type: COMPARATOR
Intervention: Control group (no relaxation training)
Number of subjects: 61
Study 21535040 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 61
Study 18294083 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (72 mg)
Number of subjects: 19
Study 18294083 — intervention group
Group type: EXPERIMENTAL
Intervention: extended-release mixed amphetamine salts (se-AMPH ER, 30 mg)
Number of subjects: 19
Study 18294083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 16547619 — intervention group
Group type: EXPERIMENTAL
Intervention: MIVAP (Minimally Invasive Video-Assisted Parathyroidectomy)
Number of subjects: 60
Study 16547619 — intervention group
Group type: COMPARATOR
Intervention: OMIP (Open Minimally Invasive Parathyroidectomy)
Number of subjects: 60
Study 12953736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of preterm infants (n=33)
Number of subjects: 60
Study 12953736 — intervention group
Group type: COMPARATOR
Intervention: Mothers of full term normal infants (n=27)
Number of subjects: 60
Study 10602721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral azithromycin
Number of subjects: 67
Study 10602721 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cefaclor
Number of subjects: 67
Study 9323621 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 8
Study 9323621 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 8
Study 31852538 — intervention group
Group type: EXPERIMENTAL
Intervention: Household visits only (Arm 1)
Number of subjects: 48
Study 31852538 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group discussions only (Arm 2)
Number of subjects: 48
Study 31852538 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both (Arm 3)
Number of subjects: 48
Study 31852538 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Arm 4)
Number of subjects: 48
Study 30481742 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptidomic identification of serum peptides using ultrafiltration and liquid chromatography‐tandem mass spectrometry (LC‐MS/MS)
Number of subjects: 200
Study 30481742 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-GDM mothers)
Number of subjects: 200
Study 27936169 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (1.5 × 10^10 CFU Ecologic® 825 + 10 g fructo‐oligosaccharides (FOS P6) per day)
Number of subjects: 20
Study 27936169 — intervention group
Group type: COMPARATOR
Intervention: Control supplements
Number of subjects: 20
Study 24694748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobedding group (receiving care in the same incubator)
Number of subjects: 100
Study 24694748 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (receiving care in separate incubators)
Number of subjects: 100
Study 22228607 — intervention group
Group type: EXPERIMENTAL
Intervention: dCIT‐TR
Number of subjects: 57
Study 22228607 — intervention group
Group type: EXPERIMENTAL
Intervention: dCIT
Number of subjects: 57
Study 22228607 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 19225400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once daily
Number of subjects: 664
Study 19225400 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) twice daily
Number of subjects: 664
Study 19225400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) once daily and twice daily
Number of subjects: 664
Study 16840982 — intervention group
Group type: COMPARATOR
Intervention: Standard injection technique
Number of subjects: 294
Study 16840982 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaject autoinjector
Number of subjects: 294
Study 16840982 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaject Light autoinjector
Number of subjects: 294
Study 15562775 — intervention group
Group type: EXPERIMENTAL
Intervention: estradiol velerate (E2V) 1.0 mg/d and medroxyprogestetone acetate (MPA) 2 mg/d
Number of subjects: 64
Study 15562775 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 64
Study 11279411 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial inferior sternotomy (ministernotomy group)
Number of subjects: 100
Study 11279411 — intervention group
Group type: COMPARATOR
Intervention: Full median sternotomy (standard sternotomy group)
Number of subjects: 100
Study 8989263 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy at a mean dose of 0.128 +/- 0.003 IU/kg.week for the first month, then 0.23 +/- 0.01 IU/kg.week, divided into daily doses (0.7-4.3 IU/day)
Number of subjects: 20
Study 8989263 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) therapy
Number of subjects: 20
Study 7684225 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost applied as an aqueous solution, hydrogels, and fatty ointment at dose levels of at least 50/25 ng/cm2 (intact/stripped skin)
Number of subjects: 73
Study 7684225 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost applied at high doses (400/150 ng/cm2)
Number of subjects: 73
Study 7684225 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost applied to large areas of skin
Number of subjects: 73
Study 7684225 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost applied at a dose of 25 micrograms/100 cm2 once daily for 60 days
Number of subjects: 73
Study 2892260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg
Number of subjects: 197
Study 2892260 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg
Number of subjects: 197
Study 29903020 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture (RA)
Number of subjects: 30
Study 29903020 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 30
Study 29903020 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (RA and SA)
Number of subjects: 30
Study 27448468 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic CPAP for 6 weeks
Number of subjects: 38
Study 27448468 — intervention group
Group type: COMPARATOR
Intervention: Placebo CPAP for 3 weeks followed by therapeutic CPAP for 3 weeks
Number of subjects: 38
Study 27448468 — intervention group
Group type: EXPERIMENTAL
Intervention: PD+OSA
Number of subjects: 38
Study 25813738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cognitive load condition
Number of subjects: 0
Study 25813738 — intervention group
Group type: EXPERIMENTAL
Intervention: High cognitive load condition
Number of subjects: 0
Study 25813738 — intervention group
Group type: EXPERIMENTAL
Intervention: First trial of judgments
Number of subjects: 0
Study 25813738 — intervention group
Group type: EXPERIMENTAL
Intervention: Second trial of judgments
Number of subjects: 0
Study 25813738 — intervention group
Group type: EXPERIMENTAL
Intervention: High WMC group
Number of subjects: 0
Study 25813738 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WMC group
Number of subjects: 0
Study 23023559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 454
Study 23023559 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose (placebo)
Number of subjects: 454
Study 20497745 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (40 mg/day) alone for 6 days
Number of subjects: 20
Study 20497745 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day) co-administered with linagliptin (10 mg/day) for 6 days
Number of subjects: 20
Study 20497745 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and linagliptin
Number of subjects: 20
Study 19096711 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation (Triomune)
Number of subjects: 18
Study 16798792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 11530
Study 16798792 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 11530
Study 16798792 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus routine care
Number of subjects: 11530
Study 12628519 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorophyllin (CHL), administered three times a day
Number of subjects: 0
Study 12628519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10835452 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA)
Number of subjects: 46
Study 10835452 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 46
Study 9090544 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt 18-gauge metal cannulae
Number of subjects: 51
Study 9090544 — intervention group
Group type: COMPARATOR
Intervention: Hypodermic needles
Number of subjects: 51
Study 8256356 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine treatment
Number of subjects: 88
Study 8256356 — intervention group
Group type: COMPARATOR
Intervention: Fucidin gauze
Number of subjects: 88
Study 3512670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg
Number of subjects: 171
Study 3512670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25.0 mg
Number of subjects: 171
Study 3512670 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 50.0 mg
Number of subjects: 171
Study 3512670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 29788364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation until delivery
Number of subjects: 800
Study 29788364 — intervention group
Group type: COMPARATOR
Intervention: Nonscreening site (no intervention)
Number of subjects: 800
Study 29788364 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 injection plus monthly 50,000 IU maintenance therapy
Number of subjects: 800
Study 29788364 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening program
Number of subjects: 800
Study 29168468 — intervention group
Group type: EXPERIMENTAL
Intervention: 1μg mometasone furoate (MF)
Number of subjects: 18
Study 29168468 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% strontium chloride (SC)
Number of subjects: 18
Study 29168468 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% strontium chloride (SC)
Number of subjects: 18
Study 29168468 — intervention group
Group type: EXPERIMENTAL
Intervention: mometasone furoate (MF)
Number of subjects: 18
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer use for health communication and monitoring
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Reading health information online
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracking health conditions online
Number of subjects: 406
Study 26176640 — intervention group
Group type: EXPERIMENTAL
Intervention: Looking at medical records online
Number of subjects: 406